BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 254 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is 1.26 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,292,565 | -17.2% | 51,029 | +1.1% | 0.05% | -21.3% |
| Q1 2024 | $1,560,656 | -16.6% | 50,474 | +8.9% | 0.06% | -23.8% |
| Q4 2023 | $1,871,028 | +31.7% | 46,347 | -14.0% | 0.08% | +1.3% |
| Q3 2023 | $1,420,526 | -12.6% | 53,869 | -43.0% | 0.08% | -9.2% |
| Q2 2023 | $1,624,798 | +93.0% | 94,465 | +86.1% | 0.09% | +67.3% |
| Q1 2023 | $841,816 | +537.7% | 50,773 | +249.0% | 0.05% | +550.0% |
| Q2 2022 | $132,000 | -21.4% | 14,549 | -11.9% | 0.01% | +14.3% |
| Q1 2022 | $168,000 | -45.1% | 16,523 | -10.0% | 0.01% | -30.0% |
| Q4 2021 | $306,000 | -68.7% | 18,362 | -12.1% | 0.01% | -69.7% |
| Q3 2021 | $979,000 | – | 20,879 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $60,317,000 | 40.05% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $308,746,000 | 6.20% |
| M28 Capital Management LP | 513,300 | $5,102,000 | 5.33% |
| GREAT POINT PARTNERS LLC | 1,050,000 | $10,437,000 | 2.51% |
| Octagon Capital Advisors LP | 933,743 | $9,281,000 | 1.60% |
| HHLR ADVISORS, LTD. | 5,362,014 | $53,298,000 | 1.40% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $264,613,000 | 1.22% |
| Cormorant Asset Management, LP | 1,469,179 | $14,604,000 | 1.02% |
| Fernwood Investment Management, LLC | 204,550 | $2,033,000 | 0.86% |
| TANG CAPITAL MANAGEMENT LLC | 585,424 | $5,819,000 | 0.71% |